Outcome of Patients with HER2-Positive Advanced Breast Cancer Progressing During Trastuzumab-Based Therapy
Autor: | Antonio Durando, M. E. Jacomuzzi, Giorgio Valabrega, Stefania Redana, Guido Vietti-Ramus, Marco Venturini, Massimo Aglietta, S. Danese, Michela Donadio, Matteo Clavarezza, Filippo Montemurro |
---|---|
Rok vydání: | 2006 |
Předmět: |
Adult
CA15-3 Oncology Cancer Research medicine.medical_specialty Advanced breast Antineoplastic Agents Breast Neoplasms Antibodies Monoclonal Humanized Central Nervous System Neoplasms Breast cancer Trastuzumab Internal medicine medicine Humans In patient skin and connective tissue diseases neoplasms Aged Retrospective Studies Aged 80 and over business.industry Antibodies Monoclonal Cancer Genes erbB-2 Middle Aged medicine.disease Survival Analysis Metastatic breast cancer Treatment Outcome Tumor progression Disease Progression Female business Follow-Up Studies medicine.drug |
Zdroj: | The Oncologist. 11:318-324 |
ISSN: | 1549-490X 1083-7159 |
Popis: | We sought to describe patterns of treatment and clinical outcome in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy. One hundred eighty-four consecutive HER2-positive advanced breast cancer patients received trastuzumab-based therapy between September 1999 and September 2004. Patients were followed up until death or May 2005. For patients progressing on trastuzumab-based therapy, we calculated the response rate (RR) to the first post-progression treatment, overall survival (OS) from the first administration of trastuzumab, time to second progression (TT-SP), and post-progression survival (PPS), according to treatment. At the time of this analysis, 132 patients had progressed on trastuzumab-based therapy, and 89 had died. Of the progressing patients, 21 experienced rapid progression and could not receive additional anticancer treatments;40 patients continued trastuzumab either alone (12 patients with isolated central nervous system progression), with chemotherapy (23 patients), or with endocrine therapy (5 patients); and 71 stopped trastuzumab and received chemotherapy (61 patients) or endocrine therapy (10 patients) as the first post-progression treatment. Excluding patients with rapid progression, clinical outcomes were similar whether trastuzumab was continued or not, in terms of RR (18% and 27%, respectively), OS (31 and 30 months, respectively), TT-SP (6 and 7 months, respectively), and PPS (21 and 19 months, respectively). The clinical outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy might not be influenced by continuing trastuzumab. The optimal therapeutic strategy in this setting of patients needs evaluation in randomized trials. |
Databáze: | OpenAIRE |
Externí odkaz: |